Initial Treatment for Atrial Flutter

Approach Based on Hemodynamic Status

The American Heart Association recommends synchronized cardioversion for patients with atrial flutter who are hemodynamically unstable, which should be performed without delay in patients with signs or symptoms of hemodynamic compromise 1, 2
For hemodynamically unstable patients, cardioversion for atrial flutter can be successful at lower energy levels than for atrial fibrillation, and appropriate anticoagulation considerations should be addressed prior to cardioversion when possible 3, 2

The American College of Cardiology recommends intravenous or oral beta blockers, diltiazem, or verapamil as first-line agents for acute rate control in hemodynamically stable patients 4, 1
Intravenous diltiazem is the preferred calcium channel blocker due to its safety and efficacy profile, and rate control is often more difficult to achieve in atrial flutter than in atrial fibrillation 2, 5
Medication selection considerations include avoiding diltiazem and verapamil in patients with advanced heart failure, heart block, or sinus node dysfunction without pacemaker therapy, and avoiding both calcium channel blockers and beta blockers in patients with pre-excitation 2

Elective synchronized cardioversion is indicated in stable patients when pursuing a rhythm-control strategy, and pharmacological cardioversion options include oral dofetilide or intravenous ibutilide, which are effective for acute pharmacological cardioversion 4, 1
Rapid atrial pacing is useful for acute conversion in patients with pacing wires already in place, such as permanent pacemaker, ICD, or temporary wires after cardiac surgery 4, 2
Caution should be exercised when using ibutilide for pharmacological cardioversion, as it can cause QT prolongation and risk of torsades de pointes, especially in patients with reduced left ventricular ejection fraction 6

The American Heart Association recommends acute antithrombotic therapy in patients with atrial flutter, following the same protocols as for atrial fibrillation, as the risk of stroke in atrial flutter is similar to that in atrial fibrillation 4, 3
Meta-analysis of studies showed thromboembolism rates averaging 3% annually in patients with sustained atrial flutter 7

For patients with atrial flutter and systolic heart failure where beta blockers are contraindicated or ineffective, intravenous amiodarone can be useful for acute rate control, according to the European Society of Cardiology 4, 8
In post-cardiac surgery patients with atrial flutter, rapid atrial pacing is particularly effective when atrial wires are already in place 2

Failing to recognize hemodynamic instability requiring immediate cardioversion, and using verapamil or diltiazem in patients with pre-excitation, which can precipitate ventricular fibrillation 2
Inadequate rate control, which is more challenging in atrial flutter than in atrial fibrillation, and underestimating stroke risk in atrial flutter patients 5, 7
Insufficient monitoring for QT prolongation when using ibutilide for pharmacological cardioversion 6

The American Heart Association recommends immediate synchronized cardioversion for hemodynamically unstable patients with atrial flutter, as stated in the Circulation journal 9
For hemodynamically stable patients, the American College of Cardiology suggests initiating rate control with intravenous or oral beta blockers, diltiazem, or verapamil, followed by consideration of catheter ablation as the definitive long-term treatment, according to the Circulation journal 9
The American College of Cardiology advises against using beta blockers, diltiazem, or verapamil in patients with pre-excited atrial flutter (Wolff-Parkinson-White syndrome), as this can precipitate ventricular fibrillation, as noted in the Journal of the American College of Cardiology 10

Catheter ablation of the cavotricuspid isthmus (CTI) is the most effective long-term treatment for typical atrial flutter, with a >90% success rate, as reported in the Circulation journal 9
The American Heart Association recommends catheter ablation for patients with symptomatic atrial flutter that is either refractory to pharmacological rate control or recurrent, according to the Circulation journal 9
The American College of Cardiology suggests that when using class IC agents (flecainide, propafenone), AV nodal blocking drugs should always be coadministered to prevent 1:1 AV conduction during atrial flutter, which can cause dangerously rapid ventricular rates, as noted in the Journal of the American College of Cardiology 10